|
In
an Australian study conducted on injured soccer players, those
that consumed Flavay™
experienced significantly less
swelling than those who did not.
Flavay™ can
help minimize damage and accelerate recovery time from
strenuous workouts, sports-related activities and
postoperative inflammation.
|
Flavay™ has been licensed and sold in France for treating
inflammation and edema (swelling) since 1950 and is now available
in the United States as a dietary supplement. Research shows
several ways that Flavay™ can help minimize damage and
accelerate recovery time from strenuous workouts and
sports-related activities.
Flavay’s™ action is synergistic for athletes: it protects
the body by helping neutralize the naturally occurring
pro-oxidative effects of strenuous workouts, and strengthens the
body’s collagen, which is a major component of muscles,
tendons, cartilage, ligaments and bones.
Flavay’s™ ability to strengthen and rebuild collagen is
important to injury-recovery because most athletic injuries
involve damaged capillaries (tiny blood vessels), caused by torn
muscles, sprains, fractures or twisting and whiplash.
Strengthening of the vascular walls in the capillaries prevents
fluids from seeping and swelling in the connective tissues.
These types of injuries are painful and usually cause other
problems, such as a loss in physical condition when the injury
causes an inability to train or compete.
In an
Australian study conducted on injured soccer players,
those that consumed Flavay™ experienced
significantly less swelling than those who did not.
|
Research has shown that Flavay’s™ ability to strengthen
vascular walls may help the body to repair injuries faster. In
an Australian study conducted on two groups of soccer players
that had sustained injuries, those that consumed Flavay™ for
ten days following their injuries experienced significantly less
swelling than those who did not and, in some of those taking
Flavay™, the swelling had completely disappeared. Other
research has demonstrated the ways in which Flavay™ may
actually inhibit inflammation including double-blind studies
conducted in France which showed that Flavay™ can also reduce
postoperative inflammation.
Natural Anti-Inflammatory
Inflammation is caused by the overproduction of free radicals
in a specific area of the body. We now know that antioxidants
work together to defeat free radicals and inhibit the biological
pathway that triggers inflammation, and Flavay™ is
particularly effective as an anti-inflammatory.
Flavay™ can
selectively bind to the connective tissue of joints,
preventing inflammation and lessening pain.
|
Flavay™ can selectively bind to the connective tissue of
joints, preventing inflammation and lessening pain. One of the
very first benefits observed and studied Dr. Jack Masquelier, in
as early as 1947, was the anti-inflammatory effect of Flavay™.
Research demonstrates that Flavay™ inhibits the release and
synthesis of histamine (which produces accelerated blood flow,
dilates capillaries and increases their permeability, thereby
leaking plasma into surrounding tissue), a key factor in the
promotion of inflammation.
Studies demonstrate that the anti-histamine action of Flavay™
is obtained through inhibiting the activity of the enzyme
histidine decarboxylase. Dr. Masquelier’s research has been
confirmed by German studies which show that Flavay™ may lower
the production of histamine with as much as 86% inhibition of
histidine decarboxylase.
Flavay™ also neutralizes free radicals that promote
swelling and cause inflammation. A free radical called
superoxide is involved in the inflammation of arthritis and
several experiments show that Flavay™ quenches the superoxide
free radicals.
Edema (Swelling)
Edema is an uncomfortable condition and can be both painful
and dangerous. Swollen and painful legs and ankles, puffiness of
the eyes and an overall bloated look and feel are examples of
edema. It involves the leakage of blood serum into surrounding
tissues and Flavay™ has shown that it can reduce this leakage
by strengthening capillary walls.
All
of those taking Flavay™ for edema (swelling) had
relief from at least some of the symptoms.
|
Italian scientists from the University of Florence studied
the effect of Flavay™ on venous congestion (edema) in the
legs. The study involved 40 subjects consisting of 13 men and 27
women between the ages of 34 and 74. The subjects were randomly
divided into two groups. One group received a placebo and the
other group received 300 mg of Flavay™ daily for 60 days.
All of those taking the Flavay™ had relief from at least
some of the symptoms. After 30 days, the pain was totally
relieved in in 38 percent of those taking Flavay™, the
swelling disappeared in 26 percent (the circumference of the
legs was measured above the ankle), and 11 percent experienced a
decrease in the feeling of heaviness in their lower limbs. After
60 days, the pain was totally relieved in 67 percent of those
taking Flavay™, the swelling disappeared in 63 percent, and
the decrease in heaviness jumped to 33 percent.
"Radical Scavenger
Effect" of Flavay™
Protected by U.S. Patent No. 4,698,360
Flavay's™ strong antioxidant power is patented—as a scavenger
of the free radicals that play a major role in the initiation,
duration and breakdown of inflammation and the degradation of
collagen.
|
"[A] method for preventing
and fighting the harmful biological effects of free
radicals in the organism of warm blooded animals
and more especially human beings, namely cerebral
involution, hypoxia following atherosclerosis,
cardiac or cerebral infarction, tumour promotion, inflammation,
ischaemia, alterations of the synovial liquid, collagen
degradation, among others. The method consists
in administering to said animals and especially to human
beings an amount, efficient against said effects, of a
plant extract with a proanthocyanidins content which has
a radical scavenger effect"—Dr.
Jack Masquelier, U.S. Patent No. 4,698,360.
|
Flavay™ is the product—used in the actual
experiments—by which Dr. Jack Masquelier
established and patented the "Radical
Scavenger Effect."
|
This means that your immune system works better so that your
joints hurt less and your blood flows better—all because of
Flavay™.
Sports and Exercise Increase
the Body's Need
for Antioxidants
Exercise
increases the body's need for antioxidants.
|
Exercise is extremely beneficial, but many do not realize
that exercise increases the body's need for antioxidants. The
fuel our bodies require for sports and exercise is oxygen. Yet
the body's production of energy from oxygen can also wreak havoc
in the body because it produces free radicals. If we are
deficient in antioxidants, the benefits of exercise are
diminished by the damage caused by free radicals. Thus, the key
to good health, is to maintain the right balance
between antioxidants and free radicals. It's not surprising,
therefore, that studies have suggested that antioxidants like
Flavay™ can actually improve athletic performance and
endurance.
Superior Antioxidant Support
Flavay™ is superior to other antioxidants because its
protective effects are multiplied in the body. While it provides
its own, powerful antioxidant protection, it also supports the
dynamic interplay between other antioxidants in the body.
Flavay's ability to “recycle,” or regenerate vitamins C and
E after they have quenched free radicals vastly extends their
unique antioxidant powers, helping to maintain an optimal,
synergistic antioxidant balance in the body.
Flavay™ is
like an antioxidant prize fighter that can
successfully take on all challengers, big or small, in
any kind of weather.
|
Flavay™ is rapidly absorbed and very quickly distributed
throughout the body. As a free radical fighter, Flavay™ comes
to the aid of the body more quickly than other antioxidants,
reducing the potential for free radical damage and the ravages
of aging. Flavay™ also possesses more reactive sites for
neutralizing free radicals than other known antioxidants.
Furthermore, Flavay™ permits reactivity with both positively
and negatively charged free radical species. What this means is
that Flavay™ can “quench” or “scavenge” (neutralize) a
broad variety of free radicals. Highly reactive as an
antioxidant in both lipid (fat) and aqueous (water) phases,
Flavay™ neutralizes oxygen free radicals and is a valuable
protector of healthy cells in a variety of internal conditions.
This is a unique property among antioxidants, as most work
either in lipid or aqueous phases, but not both. Research shows
that Flavay™ can regulate nitric oxide and quench superoxide
and the hydroxyl radical. This is extremely important. Of all
the free radicals formed in the body, the hydroxyl radical is
the most dangerous because it can directly attack DNA. As a free
radical scavenger, Flavay™ is like an antioxidant prize
fighter that can successfully take on all challengers, big or
small, in any kind of weather.
Flavay Plus™ Adds
Synergistic Help
for Regulating Stress Hormones
|
Flavay Plus™ is formulated with phosphatidyl serine
that—when given to athletes prior to starting
exercise—lowered stress hormone (cortisol)
production by 30 percent.
|
Flavay
Plus™ contains a synergistic blend of Flavay™ with
antioxidant vitamins, minerals and other phytonutrients to best
take advantage of the dynamic interplay among the antioxidants
and their co-factor nutrients. Of particular interest is
phosphatidyl serine, as research has shown that it may have the
capacity to normalize the stress-induced activation of the
above-described, "fight or flight response."
Phosphatidyl serine:
Flavay
Plus™ is formulated with phosphatidyl serine (Leci-PS™),
a complex of amino and fatty acids extracted from soy lecithin,
which has proven to be a safe, potentially effective therapeutic
agent in keeping the brain’s processes within normal limits,
raising them when they are low and lowering them when they are
high. Both physical and mental stressful conditions cause stress
hormones to be released into circulation, even in the young and
healthy. Phosphatidyl serine given to athletes prior to starting
exercise produced an impressive degree of down-regulation of the
stress hormones. Phosphatidyl serine may have the capacity to
normalize the stress-induced activation of the "fight or
flight response." In a double-blind, placebo-controlled
study conducted in Italy, phosphatidyl serine lowered stress
hormone (cortisol) production by 30 percent.
Two more recent placebo controlled studies confirmed earlier
double-blind trials; young, university students experienced
significantly less stress from tests when they took phosphatidyl
serine (300 mg daily for 30 days), they stayed more clear-headed
and composed, and kept a more stable mood.
Proven Safety of Flavay™
After more than 50 years of human use, no adverse effects
have been observed. Furthermore, intensive biological,
toxicological, pharmacological and analytical research was
conducted for the purpose of registering it as a medicine in
France and other countries in Europe. In one study, daily doses
of up to 35,000 mg for six months were determined to cause no
adverse effects. Flavay™ was also clinically tested, in
particular for all sorts of symptoms related to venolymphatic
insufficiencies (strenghthening veins, improving circulation and
reducing edema and inflammations). The spin-off is a goldmine of
data: The rigorous testing to meet the standards required by the
health ministries of France, Germany and other European
countries demonstrate that Flavay™ is highly bioavailable,
nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not
cause birth defects, and is completely safe.
Dr. Masquelier’s unequaled manufacturing process has been
conducted for half a century at the very same facilities in
France, and under the control of French Pharmaceutical
inspection. These time-proven standards serve as a reliable
assurance of the quality, consistency, bioavailability and
safety of Flavay™.
Who can take Flavay™?
Everyone, from the very young to elderly. Flavay™ has no
known contraindications (conditions under which it should not be
used). Flavay™ is completely safe and nontoxic. In fact,
clinical trials have been conducted in which pregnant women
(troubled by varicose veins and other circulatory problems in
the legs) safely used Flavay™.
Safety of Flavay Plus™
The essential vitamins and minerals in
Flavay
Plus™ are naturally-derived and completely safe. Flavay
Plus™ includes phosphatidyl serine, derived from soy lecithin,
which has been proven safe in standard toxicology tests. From
the large number of human studies conducted, phosphatidyl serine
has developed a flawless safety record and proven compatible
with a wide array of medications.
Why Trust
Flavay™
Consumers need to know that the marketplace is full of
imitations, various “extracts” and derivative forms of Dr.
Masquelier’s scientifically proven and patented complex.
Unfortunately, many have even used Dr. Masquelier’s name and
research in unauthorized ways to promote illegitimate products.
Flavay™ is the name you can trust for the precisely defined
active polyphenol complex patented and perfected by the
inventor, Dr. Jack Masquelier, validated by the French Ministry
of Health and documented by a library of research consisting of
many patents and hundreds of scientific papers, articles,
doctorate theses, lectures and presentations. For quality,
consistency, bioavailablity and safety, consumers may rely upon
Flavay™.
|
|
All About Flavay
| Flavay Plus | What Does
it Do? | Proven Safety
| Directions for Use
Q&A | Comparative Analysis | Endorsements & Testimonials
| How to Purchase
HealthyBodynMind
1-877-352-8042 • (306) 352-8042 • info@healthybodynmind.com
Protected by U.S. PATENT NO. 4,698,360 and international
patents.
Copyright © 1995-2004 Healthy Publisher.
All rights reserved. Healthy Source LLC
|
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are
not intended
to diagnose, treat, cure or prevent any disease.
|
REFERENCES:
Top  |
Masquelier, J. Plant extract with
a proanthocyanidins content as a therapeutic agent having radical scavenging
effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and
Pycnogenols. Alfa Omega
Editrice,
Pub., 1996.
Schwitters, B.,
Masquelier, J. OPC in practice. Alfa Omega
Editrice, Publishers,
1995.
Kilham, C., Masquelier, J.
OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Packer, L., et al. Antioxidant food supplements in human health. Academic
Press, 1999.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease.
Cambridge University Press, 1997.
Moncada, S., Nistico, G.,
Bagetta, G., Higgs,
E.A. Nitric oxide and the
cell. Princeton University Press, 1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats
Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains
flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii l’attachment des fibres elastiques aux cellules. (Study of the effect
of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment
of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal
structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’,
4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux
libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, “Free radicals in biotechnology
and medicine.” Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften”
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation
and characterization of endothelium-dependent vasorelaxing compounds from
grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium,
and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent
vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol
1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing
activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Kuttan, R., Donnelly,
P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia, 37:
221-223, 1981.
Masquelier, J. Procyanidolic
oligomers. J Parums Cosm
Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenols to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem.
Pharm. Bull. 33:5079, 1985.
Harmand, M.F.,
Blanquet, P. The fate of total flavanolic oligomers extracted
from ‘vitus vinifera l.’ in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J.,
Escande, B., Samain, D. Free-radical scavenging activity
of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo
and in vitro study. Cosmetology Department & S Biovectors, Ramonville
St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’une substance
capillaro-toxique chez des personnes agees--action benefique d’un agnet
actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980.
pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres
du procyanidol sur las resistance capillaire dand l’hypertension arterielle
et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique,
l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24,
1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets cirrhotiques.
Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981.
pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations
fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une
etude en double aveugle portant sur 92 patients.” Gazette Medicale,
(92)1, 1985. pp. 96-100.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate
metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty
Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris France;
Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131),
1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+)
-catechin becomes resistant to the action of mammalian collagenase.”
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat.” Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers
effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93,
1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale,
(16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A propos
de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in
rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica,
9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser
Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats,
p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members
superieurs. Symposium Satellite, Congres International d’Angiologie,
Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks
of intense training. Abstract submitted to national meeting of the Amer
College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by
chronic phosphatidylserine administration of the stress-induced activation
of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm
43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced overtraining.
Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques
sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux,
1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation
de l’acide ascorbique par les ions cuivriques. Bull. de la Societe
de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide
ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4)
1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka,
I. “Inhibitory effects of tannins on hyaluronidase activation and on
the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull.
33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine
and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress
ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase
in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique
90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int J Vit Nut
Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol.
25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells
of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects
143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover,
Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable
extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux,
129:51-65, 1990.
|
|
